Eli Lilly and Company $LLY Shares Bought by Chilton Capital Management LLC

Chilton Capital Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 29.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,682 shares of the company’s stock after acquiring an additional 20,251 shares during the quarter. Eli Lilly and Company accounts for 2.6% of Chilton Capital Management LLC’s portfolio, making the stock its 7th largest position. Chilton Capital Management LLC’s holdings in Eli Lilly and Company were worth $69,910,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Blume Capital Management Inc. lifted its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the period. Citizens National Bank Trust Department lifted its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the period. Finally, IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.6%

Shares of LLY opened at $825.86 on Friday. The business’s fifty day moving average is $768.01 and its 200-day moving average is $768.44. The firm has a market cap of $781.65 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.19 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the company posted $3.92 earnings per share. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on LLY shares. HSBC boosted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.